Autor: "Kim HS" - OpacWWW - Prolib Integro

Skocz do pozycji: 1.

Tytuł:: Risk factors for the failure of first-line PARP inhibitor maintenance therapy in patients with advanced ovarian cancer: Gynecologic Oncology Research Investigators Collaboration Study (GORILLA-3004).
Autorzy:: Kim NK; Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea.
Kim Y; Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea.
Kim HS; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
Park SJ; Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Korea.
Hwang DW; Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Korea.
Lee SJ; Department of Obstetrics and Gynecology, Seoul St. Mary's Hospital, Seoul, Korea.; Department of Obstetrics and Gynecology, The Catholic University of Korea, Seoul, Korea.
Yoo JG; Department of Obstetrics and Gynecology, Daejeon St. Mary's Hospital, The Catholic University of Korea, Daejeon, Korea.
Chang SJ; Department of Obstetrics and Gynecology, Ajou University School of Medicine, Suwon, Korea.
Son JH; Department of Obstetrics and Gynecology, Ajou University School of Medicine, Suwon, Korea.
Kong TW; Department of Obstetrics and Gynecology, Ajou University School of Medicine, Suwon, Korea.
Kim J; Department of Obstetrics and Gynecology, Ajou University School of Medicine, Suwon, Korea.
Shim SH; Department of Obstetrics and Gynecology, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Korea.
Lee AJ; Department of Obstetrics and Gynecology, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Korea.
Suh DH; Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea.; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
Lee YY; Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.; Pokaż więcej
Źródło:: Cancer medicine [Cancer Med] 2023 Oct; Vol. 12 (19), pp. 19449-19459. Date of Electronic Publication: 2023 Sep 28.
Typ publikacji:: Journal Article
MeSH Terms:: Antineoplastic Agents*/therapeutic use
Genital Neoplasms, Female*/drug therapy
Ovarian Neoplasms*/drug therapy
Ovarian Neoplasms*/genetics
Ovarian Neoplasms*/pathology
Treatment Failure*
Animals ; Female ; Humans ; Carcinoma, Ovarian Epithelial/drug therapy ; Gorilla gorilla ; Poly(ADP-ribose) Polymerase Inhibitors/adverse effects ; Retrospective Studies ; Risk Factors

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: First-Line Combination Treatment with Low-Dose Bipolar Drugs for ABCB1-Overexpressing Drug-Resistant Cancer Populations.
Autorzy:: Yoon S; School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon 16419, Republic of Korea.
Kim HS; School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon 16419, Republic of Korea.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2023 May 07; Vol. 24 (9). Date of Electronic Publication: 2023 May 07.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Neoplasm Recurrence, Local*
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Humans ; ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism ; Drug Resistance, Neoplasm ; Cell Line, Tumor ; ATP Binding Cassette Transporter, Subfamily B/genetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Contribution of Cancer-Targeting Drugs toward Faster Clinical Application.
Autorzy:: Yoon S; School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon 16419, Korea.
Kim HS; School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon 16419, Korea.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2022 Jun 09; Vol. 23 (12). Date of Electronic Publication: 2022 Jun 09.
Typ publikacji:: Editorial
MeSH Terms:: Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Neoplasms*/drug therapy
Drug Resistance, Neoplasm ; Humans

Opinia redakcyjna

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: JAK2 Inhibitor, Fedratinib, Inhibits P-gp Activity and Co-Treatment Induces Cytotoxicity in Antimitotic Drug-Treated P-gp Overexpressing Resistant KBV20C Cancer Cells.
Autorzy:: Oh Y; School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon 16419, Korea.
Lee JS; School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon 16419, Korea.
Lee JS; School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon 16419, Korea.
Park JH; School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon 16419, Korea.
Kim HS; School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon 16419, Korea.
Yoon S; School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon 16419, Korea.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2022 Apr 21; Vol. 23 (9). Date of Electronic Publication: 2022 Apr 21.
Typ publikacji:: Journal Article
MeSH Terms:: Antimitotic Agents*/pharmacology
Antineoplastic Agents*/pharmacology
Janus Kinase Inhibitors*/pharmacology
Neoplasms*/drug therapy
Neoplasms*/genetics
ATP Binding Cassette Transporter, Subfamily B, Member 1/antagonists & inhibitors ; ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics ; ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism ; Cell Line, Tumor ; Drug Resistance, Neoplasm ; Humans ; Janus Kinase 2/antagonists & inhibitors ; Janus Kinase 2/metabolism ; Pyrrolidines ; Sulfonamides ; Vincristine/pharmacology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Survival impact of additional chemotherapy after adjuvant concurrent chemoradiation in patients with early cervical cancer who underwent radical hysterectomy.
Autorzy:: Kim SI; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, 101, Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.
Kim JY; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, 101, Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.
Wee CW; Department of Radiation Oncology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, 20, Boramae-ro 5-gil, Dongjak-gu, Seoul, 07061, Republic of Korea.
Lee M; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, 101, Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.
Kim HS; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, 101, Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.
Chung HH; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, 101, Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.
Lee TS; Department of Obstetrics and Gynecology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, 20, Boramae-ro 5-gil, Dongjak-gu, Seoul, 07061, Republic of Korea.
Jeon HW; Department of Obstetrics and Gynecology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, 20, Boramae-ro 5-gil, Dongjak-gu, Seoul, 07061, Republic of Korea.
Park NH; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, 101, Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.
Song YS; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, 101, Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.
Kim TH; Department of Obstetrics and Gynecology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, 20, Boramae-ro 5-gil, Dongjak-gu, Seoul, 07061, Republic of Korea. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2021 Nov 22; Vol. 21 (1), pp. 1260. Date of Electronic Publication: 2021 Nov 22.
Typ publikacji:: Journal Article; Multicenter Study
MeSH Terms:: Chemoradiotherapy, Adjuvant*
Antineoplastic Agents/*therapeutic use
Hysterectomy/*methods
Uterine Cervical Neoplasms/*mortality
Uterine Cervical Neoplasms/*therapy
Adult ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Case-Control Studies ; Disease-Free Survival ; Female ; Humans ; Lymph Node Excision ; Lymphatic Metastasis ; Middle Aged ; Pelvis ; Risk Factors ; Survival Analysis ; Uterine Cervical Neoplasms/pathology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer: study protocol for a phase III, double-blind, randomized study.
Autorzy:: Park SJ; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
Yim GW; Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital, Goyang, Korea.
Paik H; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
Lee N; Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University School of Medicine, Seoul, Korea.
Lee S; Department of Obstetrics and Gynecology, Keimyung University School of Medicine, Daegu, Korea.
Lee M; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
Kim HS; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea. .; Pokaż więcej
Źródło:: Journal of gynecologic oncology [J Gynecol Oncol] 2021 Sep; Vol. 32 (5), pp. e73. Date of Electronic Publication: 2021 Jun 01.
Typ publikacji:: Clinical Trial Protocol; Journal Article
MeSH Terms:: Antineoplastic Agents*/adverse effects
Ovarian Neoplasms*/drug therapy
Peripheral Nervous System Diseases*/chemically induced
Peripheral Nervous System Diseases*/prevention & control
Pharmaceutical Preparations*
Selenium*/therapeutic use
Administration, Intravenous ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carboplatin/adverse effects ; Clinical Trials, Phase III as Topic ; Female ; Humans ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/prevention & control ; Paclitaxel/adverse effects ; Platinum/therapeutic use ; Quality of Life ; Randomized Controlled Trials as Topic

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Structural Basis of Inhibition of DCLK1 by Ruxolitinib.
Autorzy:: Jang DM; Research Institute, National Cancer Center, Goyang 10408, Gyeonggi, Korea.
Lim HJ; Research Institute, National Cancer Center, Goyang 10408, Gyeonggi, Korea.
Hahn H; Research Institute, National Cancer Center, Goyang 10408, Gyeonggi, Korea.
Lee Y; Research Institute, National Cancer Center, Goyang 10408, Gyeonggi, Korea.
Kim HK; Research Institute, National Cancer Center, Goyang 10408, Gyeonggi, Korea.
Kim HS; Research Institute, National Cancer Center, Goyang 10408, Gyeonggi, Korea.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2021 Aug 06; Vol. 22 (16). Date of Electronic Publication: 2021 Aug 06.
Typ publikacji:: Journal Article
MeSH Terms:: Antineoplastic Agents/*pharmacology
Intracellular Signaling Peptides and Proteins/*antagonists & inhibitors
Protein Kinase Inhibitors/*pharmacology
Protein Serine-Threonine Kinases/*antagonists & inhibitors
Pyrazoles/*pharmacology
Antineoplastic Agents/chemistry ; Doublecortin-Like Kinases ; Humans ; Intracellular Signaling Peptides and Proteins/chemistry ; Intracellular Signaling Peptides and Proteins/metabolism ; Molecular Docking Simulation ; Nitriles ; Protein Conformation/drug effects ; Protein Kinase Inhibitors/chemistry ; Protein Serine-Threonine Kinases/chemistry ; Protein Serine-Threonine Kinases/metabolism ; Pyrazoles/chemistry ; Pyrimidines

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Emerging treatments for bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer.
Autorzy:: Kim HS; Department of Urology, Dongguk University Ilsan Medical Center, Dongguk University School of Medicine, Goyang, Korea.
Seo HK; Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea.; Division of Tumor Immunology, Department of Cancer Biomedical Science, Research Institute, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea. .; Pokaż więcej
Źródło:: Investigative and clinical urology [Investig Clin Urol] 2021 Jul; Vol. 62 (4), pp. 361-377. Date of Electronic Publication: 2021 May 27.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms:: Genetic Therapy*
Antineoplastic Agents/*therapeutic use
Carcinoma, Transitional Cell/*therapy
Immune Checkpoint Inhibitors/*therapeutic use
Urinary Bladder Neoplasms/*therapy
Adjuvants, Immunologic/therapeutic use ; Administration, Intravesical ; Antineoplastic Agents/administration & dosage ; BCG Vaccine/therapeutic use ; Carcinoma, Transitional Cell/pathology ; Clinical Trials as Topic ; Genes, Viral ; Humans ; Hyperthermia ; Immunoconjugates/therapeutic use ; Organ Sparing Treatments ; Photochemotherapy ; Pyrazoles/therapeutic use ; Quinoxalines/therapeutic use ; Retreatment ; Treatment Failure ; Urinary Bladder Neoplasms/pathology

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Comprehensive analysis of oncogenic signatures and consequent repurposed drugs in TMPRSS2:ERG fusion-positive prostate cancer.
Autorzy:: Yun JW; Veterans Health Service Medical Center, Veterans Medical Research Institute, Seoul, Korea.
Lee S; Precision Medicine Center, Seoul National University Bundang Hospital, Seongnam, South Korea.; Department of Pathology and Translational Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
Chun S; Department of Laboratory Medicine, Chonnam National University Medical School and Hospital, Gwangju, Korea.
Lee KW; School of Medicine, University of Queensland, Brisbane, Australia.
Kim J; Department of Biological Sciences, Sungkyunkwan University, Suwon, Korea.
Kim HS; Department of Biological Sciences, Sungkyunkwan University, Suwon, Korea.; Pokaż więcej
Źródło:: Clinical and translational medicine [Clin Transl Med] 2021 May; Vol. 11 (5), pp. e420.
Typ publikacji:: Letter; Research Support, Non-U.S. Gov't
MeSH Terms:: Drug Repositioning*
Gene Expression Profiling*
Gene Fusion*
Antineoplastic Agents/*therapeutic use
Prostatic Neoplasms/*drug therapy
Prostatic Neoplasms/*genetics
Serine Endopeptidases/*genetics
Humans ; Male ; Transcriptional Regulator ERG/genetics

Raport

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Biological Evaluation of Oxindole Derivative as a Novel Anticancer Agent against Human Kidney Carcinoma Cells.
Autorzy:: Dey P; School of Pharmacy, Sungkyunkwan University, Suwon 16419, Korea.
Kundu A; School of Pharmacy, Sungkyunkwan University, Suwon 16419, Korea.
Han SH; School of Pharmacy, Sungkyunkwan University, Suwon 16419, Korea.
Kim KS; School of Pharmacy, Sungkyunkwan University, Suwon 16419, Korea.
Park JH; School of Pharmacy, Sungkyunkwan University, Suwon 16419, Korea.
Yoon S; School of Pharmacy, Sungkyunkwan University, Suwon 16419, Korea.
Kim IS; School of Pharmacy, Sungkyunkwan University, Suwon 16419, Korea.
Kim HS; School of Pharmacy, Sungkyunkwan University, Suwon 16419, Korea.; Pokaż więcej
Źródło:: Biomolecules [Biomolecules] 2020 Aug 31; Vol. 10 (9). Date of Electronic Publication: 2020 Aug 31.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Agents/*therapeutic use
Carcinoma, Renal Cell/*drug therapy
Kidney Neoplasms/*drug therapy
Oxindoles/*therapeutic use
Animals ; Antineoplastic Agents/pharmacology ; Apoptosis/drug effects ; Autophagy/drug effects ; Cell Cycle/drug effects ; Cell Line, Tumor ; Cell Survival/drug effects ; Humans ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Oxindoles/pharmacology ; Xenograft Model Antitumor Assays

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib.
Autorzy:: Jeon MY; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.; Yonsei Liver Cancer, Severance Hosipital, Seoul, Korea.
Lee HW; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.; Yonsei Liver Cancer, Severance Hosipital, Seoul, Korea.
Kim BK; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.; Yonsei Liver Cancer, Severance Hosipital, Seoul, Korea.; Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
Park JY; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.; Yonsei Liver Cancer, Severance Hosipital, Seoul, Korea.; Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
Kim DY; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.; Yonsei Liver Cancer, Severance Hosipital, Seoul, Korea.; Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
Ahn SH; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.; Yonsei Liver Cancer, Severance Hosipital, Seoul, Korea.; Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
Han KH; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.; Yonsei Liver Cancer, Severance Hosipital, Seoul, Korea.; Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
Baek SE; Department of Radiology, Yonsei University College of Medicine, Seoul, Korea.
Kim HS; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Kim SU; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.; Yonsei Liver Cancer, Severance Hosipital, Seoul, Korea.; Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
Park MS; Department of Radiology, Yonsei University College of Medicine, Seoul, Korea.; Pokaż więcej
Źródło:: Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2018 Sep; Vol. 38 (9), pp. 1655-1663. Date of Electronic Publication: 2018 Mar 31.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Agents/*therapeutic use
Carcinoma, Hepatocellular/*drug therapy
Liver Neoplasms/*drug therapy
Sorafenib/*therapeutic use
Aged ; Carcinoma, Hepatocellular/pathology ; Female ; Humans ; Liver/pathology ; Liver Neoplasms/pathology ; Male ; Middle Aged ; Reproducibility of Results ; Republic of Korea ; Response Evaluation Criteria in Solid Tumors ; Retrospective Studies ; Tomography, X-Ray Computed

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation.
Autorzy:: Lee HW; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Kim HS; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Kim SU; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.; Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.; Liver Cirrhosis Clinical Research Center, Seoul, Korea.
Kim DY; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.; Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.; Liver Cirrhosis Clinical Research Center, Seoul, Korea.
Kim BK; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.; Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.; Liver Cirrhosis Clinical Research Center, Seoul, Korea.
Park JY; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.; Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.; Liver Cirrhosis Clinical Research Center, Seoul, Korea.
Ahn SH; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.; Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.; Liver Cirrhosis Clinical Research Center, Seoul, Korea.
Jeon MY; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Heo JY; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Park SY; Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.
Lee YR; Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.
Jang SK; Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.
Lee SH; Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.
Jang SY; Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.
Tak WY; Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.
Han KH; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.; Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.; Liver Cirrhosis Clinical Research Center, Seoul, Korea.; Pokaż więcej
Źródło:: Gut and liver [Gut Liver] 2017 Sep 15; Vol. 11 (5), pp. 693-701.
Typ publikacji:: Journal Article; Validation Study
MeSH Terms:: Antineoplastic Agents*
Phenylurea Compounds*
Severity of Illness Index*
Carcinoma, Hepatocellular/*mortality
Liver Neoplasms/*mortality
Niacinamide/*analogs & derivatives
Withholding Treatment/*statistics & numerical data
Aged ; Area Under Curve ; Carcinoma, Hepatocellular/drug therapy ; Female ; Humans ; Liver Neoplasms/drug therapy ; Male ; Middle Aged ; ROC Curve ; Retrospective Studies ; Risk Factors ; Sorafenib ; Survival Rate

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: In vitro biologic efficacy of sunitinib drug-eluting beads on human colorectal and hepatocellular carcinoma-A pilot study.
Autorzy:: Lahti S; Interventional Oncology Translational Laboratory, Pittsburgh School of Medicine, Presbyterian South Tower, Pittsburgh, PA, United States of America.
Ludwig JM; Interventional Oncology Translational Laboratory, Pittsburgh School of Medicine, Presbyterian South Tower, Pittsburgh, PA, United States of America.; Division of Interventional Radiology, Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, United States of America.
Xing M; Interventional Oncology Translational Laboratory, Pittsburgh School of Medicine, Presbyterian South Tower, Pittsburgh, PA, United States of America.; Division of Interventional Radiology, Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, United States of America.
Sun L; Molecular Imaging Laboratory, Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States of America.
Zeng D; Molecular Imaging Laboratory, Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States of America.
Kim HS; Interventional Oncology Translational Laboratory, Pittsburgh School of Medicine, Presbyterian South Tower, Pittsburgh, PA, United States of America.; Division of Interventional Radiology, Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, United States of America.; Yale Cancer Center, Yale School of Medicine, New Haven, New Haven, CT, United States of America.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2017 Apr 06; Vol. 12 (4), pp. e0174539. Date of Electronic Publication: 2017 Apr 06 (Print Publication: 2017).
Typ publikacji:: Journal Article
MeSH Terms:: Drug-Eluting Stents*
Antineoplastic Agents/*administration & dosage
Carcinoma, Hepatocellular/*pathology
Colorectal Neoplasms/*pathology
Indoles/*administration & dosage
Liver Neoplasms/*pathology
Pyrroles/*administration & dosage
Antineoplastic Agents/pharmacokinetics ; Cell Line, Tumor ; Chromatography, High Pressure Liquid ; Humans ; In Vitro Techniques ; Indoles/pharmacokinetics ; Pyrroles/pharmacokinetics ; Sunitinib

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: Identification of Pharmacologically Tractable Protein Complexes in Cancer Using the R-Based Network Clustering and Visualization Program MCODER.
Autorzy:: Kwon S; Graduate Programs for Nanomedical Science, Yonsei University, Seoul, Republic of Korea.
Kim H; Severance Biomedical Science Institute, Brain Korea 21 Plus Project for Medical Science, Yonsei University, College of Medicine, Seoul, Republic of Korea.
Kim HS; Graduate Programs for Nanomedical Science, Yonsei University, Seoul, Republic of Korea.; Severance Biomedical Science Institute, Brain Korea 21 Plus Project for Medical Science, Yonsei University, College of Medicine, Seoul, Republic of Korea.; Pokaż więcej
Źródło:: BioMed research international [Biomed Res Int] 2017; Vol. 2017, pp. 1016305. Date of Electronic Publication: 2017 Jun 13.
Typ publikacji:: Journal Article
MeSH Terms:: Software*
Antineoplastic Agents/*pharmacology
Multiprotein Complexes/*metabolism
Neoplasm Proteins/*metabolism
Neoplasms/*metabolism
Cluster Analysis ; Humans ; Time Factors

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs.
Autorzy:: Lee SJ; Research Institute, National Cancer Center, Goyang, Gyeonggi, Korea.; The Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Korea.
Choi JS; Oscotec Inc., Seongnam, Gyeonggi, Korea.
Han BG; Research Institute, National Cancer Center, Goyang, Gyeonggi, Korea.
Kim HS; Research Institute, National Cancer Center, Goyang, Gyeonggi, Korea.
Song HJ; Genosco, Cambridge, MA, USA.
Lee J; Genosco, Cambridge, MA, USA.
Nam S; Department of Life Sciences, College of BioNano Technology, Gachon University, Sungnam, Korea.; Department of Genome Medicine and Science, Graduate School of Medicine, Gachon University, Incheon, Korea.
Goh SH; Research Institute, National Cancer Center, Goyang, Gyeonggi, Korea.
Kim JH; Oscotec Inc., Seongnam, Gyeonggi, Korea.
Koh JS; Genosco, Cambridge, MA, USA. .
Lee BI; Research Institute, National Cancer Center, Goyang, Gyeonggi, Korea. .; Pokaż więcej
Źródło:: The FEBS journal [FEBS J] 2016 Oct; Vol. 283 (19), pp. 3613-3625.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Agents/*chemistry
Protein Kinase Inhibitors/*chemistry
Syk Kinase/*antagonists & inhibitors
Syk Kinase/*chemistry
Antineoplastic Agents/pharmacology ; Crystallography, X-Ray ; Drug Design ; Indazoles/chemistry ; Models, Molecular ; Oxazines/chemistry ; Protein Kinase Inhibitors/pharmacology ; Pyrazines/chemistry ; Pyridines/chemistry

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: Mica Nanoparticle, STB-HO Eliminates the Human Breast Carcinoma Cells by Regulating the Interaction of Tumor with its Immune Microenvironment.
Autorzy:: Kang TW; Adult Stem Cell Research Center, College of Veterinary Medicine, Seoul National University, Seoul 151-742, South Korea.; Institute for Stem Cell and Regenerative Medicine in Kangstem Biotech, Biomedical Science Building, College of Veterinary Medicine, Seoul National University, Seoul 151-742, South Korea.
Kim HS; Adult Stem Cell Research Center, College of Veterinary Medicine, Seoul National University, Seoul 151-742, South Korea.; Institute for Stem Cell and Regenerative Medicine in Kangstem Biotech, Biomedical Science Building, College of Veterinary Medicine, Seoul National University, Seoul 151-742, South Korea.
Lee BC; Adult Stem Cell Research Center, College of Veterinary Medicine, Seoul National University, Seoul 151-742, South Korea.; Research Institute for Veterinary Medicine, College of Veterinary Medicine, Seoul National University, Seoul 151-742, South Korea.
Shin TH; Adult Stem Cell Research Center, College of Veterinary Medicine, Seoul National University, Seoul 151-742, South Korea.; Research Institute for Veterinary Medicine, College of Veterinary Medicine, Seoul National University, Seoul 151-742, South Korea.
Choi SW; Adult Stem Cell Research Center, College of Veterinary Medicine, Seoul National University, Seoul 151-742, South Korea.; Research Institute for Veterinary Medicine, College of Veterinary Medicine, Seoul National University, Seoul 151-742, South Korea.
Kim YJ; Institute for Stem Cell and Regenerative Medicine in Kangstem Biotech, Biomedical Science Building, College of Veterinary Medicine, Seoul National University, Seoul 151-742, South Korea.
Lee HY; Institute for Stem Cell and Regenerative Medicine in Kangstem Biotech, Biomedical Science Building, College of Veterinary Medicine, Seoul National University, Seoul 151-742, South Korea.; The Faculty of Liberal Arts, Jungwon University, Chungbuk, 367-805, South Korea.
Jung YK; Seobong BioBestech Co., Ltd., Yeoksam-dong, Kangnam-gu, Seoul, South Korea.
Seo KW; Research Institute for Veterinary Medicine, College of Veterinary Medicine, Seoul National University, Seoul 151-742, South Korea.; Institute for Stem Cell and Regenerative Medicine in Kangstem Biotech, Biomedical Science Building, College of Veterinary Medicine, Seoul National University, Seoul 151-742, South Korea.
Kang KS; Adult Stem Cell Research Center, College of Veterinary Medicine, Seoul National University, Seoul 151-742, South Korea.; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2015 Dec 03; Vol. 5, pp. 17515. Date of Electronic Publication: 2015 Dec 03.
Typ publikacji:: Journal Article
MeSH Terms:: Aluminum Silicates/*pharmacology
Antineoplastic Agents/*pharmacology
Breast Neoplasms/*drug therapy
Tumor Microenvironment/*immunology
Aluminum Silicates/administration & dosage ; Aluminum Silicates/chemistry ; Animals ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/chemistry ; Breast Neoplasms/immunology ; Breast Neoplasms/pathology ; Cell Proliferation/drug effects ; Dendritic Cells/drug effects ; Female ; Humans ; Killer Cells, Natural/drug effects ; Killer Cells, Natural/immunology ; MCF-7 Cells/drug effects ; Macrophages/drug effects ; Mice, Nude ; Nanoparticles/chemistry ; Tumor Microenvironment/drug effects ; Xenograft Model Antitumor Assays

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine.
Autorzy:: Lee CK; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Jung M; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Choi HJ; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Kim HR; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Kim HS; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Roh MR; Department of Dermatology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Ahn JB; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Chung HC; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Heo SJ; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Rha SY; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Shin SJ; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.; Pokaż więcej
Źródło:: Cancer research and treatment [Cancer Res Treat] 2015 Oct; Vol. 47 (4), pp. 781-9. Date of Electronic Publication: 2015 Feb 16.
Typ publikacji:: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Agents/*therapeutic use
Carboplatin/*therapeutic use
Dacarbazine/*therapeutic use
Melanoma/*drug therapy
Taxoids/*therapeutic use
Adult ; Aged ; Antineoplastic Agents/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols ; Carboplatin/administration & dosage ; Carboplatin/adverse effects ; Dacarbazine/administration & dosage ; Dacarbazine/adverse effects ; Docetaxel ; Female ; Humans ; Male ; Middle Aged ; Patient Compliance ; Taxoids/administration & dosage ; Taxoids/adverse effects ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Mechanism of Cisplatin-Induced Cytotoxicity Is Correlated to Impaired Metabolism Due to Mitochondrial ROS Generation.
Autorzy:: Choi YM; Department of Molecular Science and Technology, Ajou University, Suwon, 443-749, Korea.
Kim HK; Department of Molecular Science and Technology, Ajou University, Suwon, 443-749, Korea.
Shim W; Department of Molecular Science and Technology, Ajou University, Suwon, 443-749, Korea.
Anwar MA; Department of Molecular Science and Technology, Ajou University, Suwon, 443-749, Korea.
Kwon JW; Department of Molecular Science and Technology, Ajou University, Suwon, 443-749, Korea.
Kwon HK; Department of Molecular Science and Technology, Ajou University, Suwon, 443-749, Korea.
Kim HJ; Division of Energy Systems Research, Ajou University, Suwon, 443-749, Korea.
Jeong H; School of Interdisciplinary Bioscience and Bioengineering, POSTECH, Pohang, 790-784, Korea.
Kim HM; Division of Energy Systems Research, Ajou University, Suwon, 443-749, Korea.
Hwang D; School of Interdisciplinary Bioscience and Bioengineering, POSTECH, Pohang, 790-784, Korea.
Kim HS; School of Pharmacy, Sungkyunkwan University, Suwon, 440-746, Korea.
Choi S; Department of Molecular Science and Technology, Ajou University, Suwon, 443-749, Korea.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2015 Aug 06; Vol. 10 (8), pp. e0135083. Date of Electronic Publication: 2015 Aug 06 (Print Publication: 2015).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Agents/*toxicity
Cisplatin/*toxicity
Citric Acid Cycle/*drug effects
Glycolysis/*drug effects
Membrane Potential, Mitochondrial/*drug effects
Reactive Oxygen Species/*agonists
Acetylcysteine/pharmacology ; Animals ; Apoptosis/drug effects ; Cell Line ; Cell Proliferation/drug effects ; Dose-Response Relationship, Drug ; Epithelial Cells/cytology ; Epithelial Cells/drug effects ; Epithelial Cells/metabolism ; Gene Expression Regulation ; Humans ; Injections, Intraperitoneal ; Kidney Tubules/cytology ; Kidney Tubules/drug effects ; Kidney Tubules/metabolism ; L-Lactate Dehydrogenase/genetics ; L-Lactate Dehydrogenase/metabolism ; Male ; Rats ; Rats, Sprague-Dawley ; Reactive Oxygen Species/metabolism ; Tumor Suppressor Protein p53/agonists ; Tumor Suppressor Protein p53/genetics ; Tumor Suppressor Protein p53/metabolism

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: Mode of action and pharmacogenomic biomarkers for exceptional responders to didemnin B.
Autorzy:: Potts MB; Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
McMillan EA; Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Rosales TI; Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Kim HS; Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Ou YH; Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Toombs JE; Division of Surgical Oncology, Department of Surgery, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Brekken RA; Division of Surgical Oncology, Department of Surgery, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Minden MD; 1] Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada. [2] Ontario Cancer Institute and Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada.
MacMillan JB; Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
White MA; Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.; Pokaż więcej
Źródło:: Nature chemical biology [Nat Chem Biol] 2015 Jun; Vol. 11 (6), pp. 401-8. Date of Electronic Publication: 2015 Apr 13.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Pharmacogenetics*
Antineoplastic Agents/*pharmacology
Apoptosis/*drug effects
Depsipeptides/*pharmacology
Membrane Proteins/*antagonists & inhibitors
Peptide Elongation Factor 1/*antagonists & inhibitors
Apoptosis/genetics ; Biomarkers/metabolism ; Cell Line, Tumor ; Genome-Wide Association Study ; Humans ; Mechanistic Target of Rapamycin Complex 1 ; Membrane Proteins/genetics ; Multiprotein Complexes/genetics ; Multiprotein Complexes/metabolism ; Peptide Elongation Factor 1/genetics ; Protein Biosynthesis/drug effects ; Protein Biosynthesis/genetics ; TOR Serine-Threonine Kinases/genetics ; TOR Serine-Threonine Kinases/metabolism ; Thiolester Hydrolases ; Transcription Factors/antagonists & inhibitors ; Transcription Factors/genetics

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
Autorzy:: Lee SH; Department of Internal Medicine, Soonchunhyang University College of Medicine, Cheonan, Republic of Korea. .
Song IH; Department of Internal Medicine, Dankook University College of Medicine, 201 Manghyang-ro, Dongnam-gu, Cheonan, 330-715, Republic of Korea. .
Noh R; Department of Internal Medicine, Dankook University College of Medicine, 201 Manghyang-ro, Dongnam-gu, Cheonan, 330-715, Republic of Korea. .
Kang HY; Department of Internal Medicine, Dankook University College of Medicine, 201 Manghyang-ro, Dongnam-gu, Cheonan, 330-715, Republic of Korea. .
Kim SB; Department of Internal Medicine, Dankook University College of Medicine, 201 Manghyang-ro, Dongnam-gu, Cheonan, 330-715, Republic of Korea. .
Ko SY; Department of Internal Medicine, Konkuk University School of Medicine, Chungju, Republic of Korea. .
Lee ES; Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Republic of Korea. .
Kim SH; Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Republic of Korea. .
Lee BS; Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Republic of Korea. .
Kim AN; Department of Internal Medicine, Eulji University College of Medicine, Daejeon, Republic of Korea. .
Chae HB; Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Republic of Korea. .
Kim HS; Department of Internal Medicine, Soonchunhyang University College of Medicine, Cheonan, Republic of Korea. .
Lee TH; Department of Internal Medicine, Konyang University College of Medicine, Daejeon, Republic of Korea. .
Kang YW; Department of Internal Medicine, Konyang University College of Medicine, Daejeon, Republic of Korea. .
Lee JD; Department of Internal Medicine, Konkuk University School of Medicine, Chungju, Republic of Korea. .
Lee HY; Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Republic of Korea. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2015 Apr 08; Vol. 15, pp. 236. Date of Electronic Publication: 2015 Apr 08.
Typ publikacji:: Journal Article; Multicenter Study
MeSH Terms:: Antineoplastic Agents/*therapeutic use
Carcinoma, Hepatocellular/*drug therapy
Carcinoma, Hepatocellular/*pathology
Liver Neoplasms/*drug therapy
Liver Neoplasms/*pathology
Niacinamide/*analogs & derivatives
Phenylurea Compounds/*therapeutic use
Protein Kinase Inhibitors/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/adverse effects ; Carcinoma, Hepatocellular/etiology ; Carcinoma, Hepatocellular/mortality ; Female ; Humans ; Liver Neoplasms/etiology ; Liver Neoplasms/mortality ; Male ; Middle Aged ; Neoplasm Staging ; Niacinamide/adverse effects ; Niacinamide/therapeutic use ; Phenylurea Compounds/adverse effects ; Prognosis ; Protein Kinase Inhibitors/adverse effects ; Retrospective Studies ; Risk Factors ; Sorafenib ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Kim HS"" wg kryterium: Autor

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język